Will ET-02 cure hair loss? Or is it just more hype?

Linked video:
   • PAI-1 and ET-02:  the secret to stopp...  

Sources:
1. Placencio VR, DeClerck YA. Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing. Cancer Res. 2015;75(15):2969-2974. doi:10.1158/0008-5472.CAN-15-0876
2. Taeye BMD, Novitskaya T, Gleaves L, Covington JW, Vaughan DE. Bone Marrow Plasminogen Activator Inhibitor-1 Influences the Development of Obesity *. Journal of Biological Chemistry. 2006;281(43):32796-32805. doi:10.1074/jbc.M606214200
3. Coin Flip Probability Calculator. Omni Calculator. July 25, 2024. Accessed January 9, 2025. https://www.omnicalculator.com/statis...
4. Liu YX, Peng XR, Liu HZ, Chen YJ, Ny T. Prolactin Regulation of Tissue Type Plasminogen Activator and Plasminogen Activator Inhibitor Type-I Gene Expression in eCG-Primed Rat Granulosa Cells in Culture1. Biology of Reproduction. 1998;59(2):409-416. doi:10.1095/biolreprod59.2.409
5. Inc ET. Eirion Therapeutics Announces Potential Breakthrough Treatment for Hair Loss Based on First-in-Man Clinical Trial Results. Accessed January 8, 2025. https://www.prnewswire.com/news-relea...
6. Khan SS, Shah SJ, Klyachko E, et al. A null mutation in SERPINE1 protects against biological aging in humans. Science Advances. 2017;3(11):eaao1617. doi:10.1126/sciadv.aao1617
7. Kortlever RM, Higgins PJ, Bernards R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol. 2006;8(8):877-884. doi:10.1038/ncb1448
8. Baluta MM, Vintila MM. PAI-1 Inhibition – Another Therapeutic Option for Cardiovascular Protection. Maedica (Bucur). 2015;10(2):147-152. Accessed March 14, 2023. https://www.ncbi.nlm.nih.gov/pmc/arti...
9. Edelson J. Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors. Published online March 19, 2020. Accessed March 14, 2023. https://patents.google.com/patent/WO2...
10. EdiGene (GuangZhou) Inc. An Exploratory,Open-Label,and Single Center Study to Evaluate the Safety and Efficacy of ET-02 in Patients With Relapsed or Refractory B-Cell Malignancies(NHL/ALL). clinicaltrials.gov; 2023. Accessed March 13, 2023. https://clinicaltrials.gov/ct2/show/N...
11. PIPELINE. Eirion. Accessed March 14, 2023. https://moonink6.wixsite.com/eirion/p...
12. Kumar TR, Larson M, Wang H, McDermott J, Bronshteyn I. Transgenic Mouse Technology: Principles and Methods. Methods Mol Biol. 2009;590:335-362. doi:10.1007/978-1-60327-378-7_22
13. Vaughan DE, De Taeye BM, Eren M. PAI-1 antagonists: predictable indications and unconventional applications. Curr Drug Targets. 2007;8(9):962-970. doi:10.2174/138945007781662364
14. Eren M, Gleaves LA, Atkinson JB, King LE, Declerck PJ, Vaughan DE. Reactive site-dependent phenotypic alterations in plasminogen activator inhibitor-1 transgenic mice. J Thromb Haemost. 2007;5(7):1500-1508. doi:10.1111/j.1538-7836.2007.02587.x
15. Vaughan DE. PAI-1 Antagonists: The Promise and the Peril. Trans Am Clin Climatol Assoc. 2011;122:312-325. Accessed March 11, 2023. https://www.ncbi.nlm.nih.gov/pmc/arti...
16. Colavincenzo M. Evaluating PAI-1 Expression in the Hair Follicles of Patients With Non-Scarring Hair Loss. clinicaltrials.gov; 2022. Accessed March 9, 2023. https://clinicaltrials.gov/ct2/show/N...